Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.996 SEK
−101.62 M SEK
0.00 SEK
45.04 M
About MENDUS AB
Sector
Industry
CEO
Erik Manting
Website
Headquarters
Stockholm
Founded
2002
ISIN
SE0022239950
FIGI
BBG004G0BR10
Mendus AB is a clinical-level biopharmaceutical company, which engages in the provision of allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. It operates under the Sweden and Netherlands geographic segments. The company was founded by Bengt Anders Andersson, Alex Karlsson-Parra, and AnnaCarin Wallgren in 2002 and is headquartered in Stockholm, Sweden.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMMU is 10.000 SEK — it has decreased by −2.86% in the past 24 hours. Watch MENDUS AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange MENDUS AB stocks are traded under the ticker IMMU.
IMMU stock has fallen by −2.91% compared to the previous week, the month change is a 25.00% rise, over the last year MENDUS AB has showed a 37.36% increase.
We've gathered analysts' opinions on MENDUS AB future price: according to them, IMMU price has a max estimate of 36.00 SEK and a min estimate of 14.00 SEK. Watch IMMU chart and read a more detailed MENDUS AB stock forecast: see what analysts think of MENDUS AB and suggest that you do with its stocks.
IMMU reached its all-time high on Dec 5, 2013 with the price of 838.420 SEK, and its all-time low was 6.000 SEK and was reached on Aug 31, 2023. View more price dynamics on IMMU chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IMMU stock is 6.80% volatile and has beta coefficient of 0.59. Track MENDUS AB stock price on the chart and check out the list of the most volatile stocks — is MENDUS AB there?
Today MENDUS AB has the market capitalization of 503.60 M, it has increased by 0.99% over the last week.
Yes, you can track MENDUS AB financials in yearly and quarterly reports right on TradingView.
MENDUS AB is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
IMMU earnings for the last quarter are −0.70 SEK per share, whereas the estimation was −0.70 SEK resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.72 SEK per share. See more details about MENDUS AB earnings.
MENDUS AB revenue for the last quarter amounts to 0.00 SEK, matching the estimated figure, and no changes in revenue are expected for the next quarter.
IMMU net income for the last quarter is −23.03 M SEK, while the quarter before that showed −38.24 M SEK of net income which accounts for 39.78% change. Track more MENDUS AB financial stats to get the full picture.
No, IMMU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMMU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MENDUS AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MENDUS AB technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MENDUS AB stock shows the sell signal. See more of MENDUS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.